Table 1.

Baseline demographics (n = 42)^*

Age, y	72.4 ± 5.7
Education, y	16.9 ± 2.2
Women, n	15 (35.7%)
Race, Caucasian, n	39 (92.9%)
APOE4+, n	11 (26.2%)
Interval between tau and amyloid imaging, d	3.6 ± 2.7
Interval between tau imaging and clinical assessment, d	3.0 ± 2.1
Interval between tau imaging and driving assessment, d	90 ± 197.6
PET Imaging
Florbetapir SUVR	1.4 ± 0.7
Flortaucipir SUVR	1.2 ± 0.2
Amyloid (+)	21 (44.7%)
Tau (+)	12 (28.6%)
Imaging Groups
Preclinical Stage 0: – amyloid – tau	21 (44.7%)
Preclinical Stage 1: +amyloid – tau	9 (19.1%)
Preclinical Stage 2: +amyloid + tau	12 (25.5%)
MMSE	29.3 ± 1.02
Road Test Rating (Pass)	37 (88.1%)

APOE, apolipoprotein ε; PET, positron emission tomography; SUVR, standardized uptake value ratio; MMSE, Mini-Mental State Examination.

^*Mean or number ± SD or percentage.